CN117164696A - Production method of recombinant human bone morphogenetic protein-2 mature peptide dimer - Google Patents
Production method of recombinant human bone morphogenetic protein-2 mature peptide dimer Download PDFInfo
- Publication number
- CN117164696A CN117164696A CN202311451465.4A CN202311451465A CN117164696A CN 117164696 A CN117164696 A CN 117164696A CN 202311451465 A CN202311451465 A CN 202311451465A CN 117164696 A CN117164696 A CN 117164696A
- Authority
- CN
- China
- Prior art keywords
- protein
- buffer solution
- supernatant
- sodium phosphate
- renaturation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 32
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 31
- 239000000539 dimer Substances 0.000 title claims abstract description 27
- 108010023714 recombinant human bone morphogenetic protein-2 Proteins 0.000 title abstract description 30
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 88
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 86
- 210000003000 inclusion body Anatomy 0.000 claims abstract description 42
- 238000004153 renaturation Methods 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 32
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims abstract description 31
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims abstract description 29
- 238000004925 denaturation Methods 0.000 claims abstract description 25
- 230000036425 denaturation Effects 0.000 claims abstract description 25
- 238000000746 purification Methods 0.000 claims abstract description 14
- 238000001742 protein purification Methods 0.000 claims abstract description 7
- 235000018102 proteins Nutrition 0.000 claims description 80
- 239000000243 solution Substances 0.000 claims description 34
- 239000007853 buffer solution Substances 0.000 claims description 27
- 239000012064 sodium phosphate buffer Substances 0.000 claims description 27
- 239000006228 supernatant Substances 0.000 claims description 25
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 23
- 239000004202 carbamide Substances 0.000 claims description 23
- 239000000872 buffer Substances 0.000 claims description 16
- 238000011068 loading method Methods 0.000 claims description 14
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 13
- 229940124280 l-arginine Drugs 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 210000000988 bone and bone Anatomy 0.000 claims description 12
- 239000002244 precipitate Substances 0.000 claims description 10
- 239000012149 elution buffer Substances 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 9
- 230000000921 morphogenic effect Effects 0.000 claims description 9
- 238000000108 ultra-filtration Methods 0.000 claims description 9
- FZKVFWQMTJFRGP-UHFFFAOYSA-N 2-cyclohexylethanesulfonic acid Chemical compound OS(=O)(=O)CCC1CCCCC1 FZKVFWQMTJFRGP-UHFFFAOYSA-N 0.000 claims description 8
- 239000011534 wash buffer Substances 0.000 claims description 8
- 238000006073 displacement reaction Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 230000001965 increasing effect Effects 0.000 claims description 7
- 238000007664 blowing Methods 0.000 claims description 6
- 238000005341 cation exchange Methods 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000013049 sediment Substances 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 229960003067 cystine Drugs 0.000 claims description 3
- 229960000789 guanidine hydrochloride Drugs 0.000 claims description 3
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 2
- 238000011010 flushing procedure Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 abstract description 10
- 238000004587 chromatography analysis Methods 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 7
- 238000001502 gel electrophoresis Methods 0.000 description 7
- 238000005457 optimization Methods 0.000 description 7
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000001042 affinity chromatography Methods 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 3
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229940112869 bone morphogenetic protein Drugs 0.000 description 3
- 102000045896 human BMP2 Human genes 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000008143 Bone Morphogenetic Protein 2 Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001447056 Uristes Species 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- 239000013636 protein dimer Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 1
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101710167839 Morphogenetic protein Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 230000001002 morphogenetic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012784 weak cation exchange Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311451465.4A CN117164696B (en) | 2023-11-03 | 2023-11-03 | Production method of recombinant human bone morphogenetic protein-2 mature peptide dimer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311451465.4A CN117164696B (en) | 2023-11-03 | 2023-11-03 | Production method of recombinant human bone morphogenetic protein-2 mature peptide dimer |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117164696A true CN117164696A (en) | 2023-12-05 |
CN117164696B CN117164696B (en) | 2024-03-22 |
Family
ID=88947295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311451465.4A Active CN117164696B (en) | 2023-11-03 | 2023-11-03 | Production method of recombinant human bone morphogenetic protein-2 mature peptide dimer |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117164696B (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1757723A (en) * | 2005-07-07 | 2006-04-12 | 徐放 | Method of producing recombination human bone morphopoiesis protein |
CN102336829A (en) * | 2010-09-09 | 2012-02-01 | 杭州九源基因工程有限公司 | Method for producing recombinant human bone morphogenetic protein-2 mature peptide |
CN104277118A (en) * | 2014-07-14 | 2015-01-14 | 天津科技大学 | Heterodimer protein of recombinant human bone morphogenetic protein and efficient expression and renaturation method of heterodimer protein |
CN115873095A (en) * | 2022-12-15 | 2023-03-31 | 烟台正海生物科技股份有限公司 | Purification method of recombinant human bone morphogenetic protein-2 dimer |
-
2023
- 2023-11-03 CN CN202311451465.4A patent/CN117164696B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1757723A (en) * | 2005-07-07 | 2006-04-12 | 徐放 | Method of producing recombination human bone morphopoiesis protein |
CN102336829A (en) * | 2010-09-09 | 2012-02-01 | 杭州九源基因工程有限公司 | Method for producing recombinant human bone morphogenetic protein-2 mature peptide |
CN104277118A (en) * | 2014-07-14 | 2015-01-14 | 天津科技大学 | Heterodimer protein of recombinant human bone morphogenetic protein and efficient expression and renaturation method of heterodimer protein |
CN115873095A (en) * | 2022-12-15 | 2023-03-31 | 烟台正海生物科技股份有限公司 | Purification method of recombinant human bone morphogenetic protein-2 dimer |
Non-Patent Citations (3)
Title |
---|
DAVOOD NASRABADI等: "Inclusion Body Expression and Refolding of Recombinant Bone Morphogenetic Protein-2", 《AVICENNA J MED BIOTECHNOL》, vol. 10, no. 4 * |
TOBIAS HEINKS等: "Optimized expression and purification of a soluble BMP2 variant based on in-silico design", 《PROTEIN EXPRESSION AND PURIFICATINO》, vol. 186, pages 1 - 10 * |
赵玮钦等: "不同复性方法制备的rhBMP-2m诱导异位成骨活性比较", 《第四军医大学学报》, vol. 28, no. 7, pages 1 * |
Also Published As
Publication number | Publication date |
---|---|
CN117164696B (en) | 2024-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101868858B1 (en) | Method for Purifying Human Serum Albumin from Transgenic Rice Grain | |
EP1127063B1 (en) | Methods of purifying recombinant human erythropoietin from cell culture supernatants | |
KR101831300B1 (en) | Method of purifying human granulocyte-colony stimulating factor from recombinant e. coli | |
CN106478801A (en) | A kind of method separating recombinant human nerve growth factor from mammalian cell cultures | |
CN112210002B (en) | Purification method of recombinant human serum albumin | |
EP1869078A2 (en) | Process for the purification of recombinant granulocyte-colony stimulating factor | |
EP0949335B2 (en) | Process for preparing purified dimer of bone-derived factor | |
EA035448B1 (en) | PROCESS FOR PURIFICATION OF rHu-GCSF | |
CN117164696B (en) | Production method of recombinant human bone morphogenetic protein-2 mature peptide dimer | |
CN113121637B (en) | Separation and purification method of recombinant protein | |
CN115873095A (en) | Purification method of recombinant human bone morphogenetic protein-2 dimer | |
US6492327B2 (en) | Isolation of purified TGF- β1 and TGF -β2 from bone tissue | |
CN108368162A (en) | A kind of renaturation and purification process of recombined human granulocyte stimulating factors | |
CN102336829B (en) | Method for producing recombinant human bone morphogenetic protein-2 mature peptide | |
CA2050318A1 (en) | Endothelial cell growth factor, methods of isolation and expression | |
CN112175063B (en) | Process for preparing high-purity recombinant epidermal growth factor by high performance liquid chromatography | |
EP1449848A1 (en) | Method for the production of cystine-knot proteins | |
CN107759683A (en) | A kind of large-scale preparation method of Human bone morphogenetic protein | |
CN112209999B (en) | Method for quickly separating pigment in recombinant epidermal growth factor fermentation liquor | |
CN103102417B (en) | Purification method of recombinant human interferon alpha 2b-CTP fusion protein | |
WO2005054287A1 (en) | Process for producing human interferon alpha | |
CN117362443A (en) | Purification method of recombinant leukocyte inhibitory factor and hirudin chimeric protein | |
RU2487885C2 (en) | Method for large-scale production, separation and purification of recombinant human granulocyte colony-stimulating factor | |
CN114213525A (en) | Method for purifying growth hormone | |
US20050026247A1 (en) | Process for preparing purified active monomer of bone-derived factor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhao Suli Inventor after: Xie Penghui Inventor after: Kang Shujing Inventor after: Wang Juncha Inventor after: Wang Gang Inventor after: Xu Kuixue Inventor after: Shi Chunsheng Inventor after: Sun Taojian Inventor after: Wang Lulu Inventor after: Song Yazhou Inventor after: Geng Dai Inventor after: Ding Zhenxun Inventor after: Diao Aipo Inventor after: Zhao Qing Inventor after: Li Yuyin Inventor after: Hu Chunyi Inventor after: Wu Qian Inventor after: Song Ningning Inventor after: Yue Shujun Inventor before: Zhao Suli Inventor before: Xu Kuixue Inventor before: Shi Chunsheng Inventor before: Sun Taojian Inventor before: Wang Lulu Inventor before: Xie Penghui Inventor before: Yue Shujun Inventor before: Wu Qian Inventor before: Song Ningning Inventor before: Kang Shujing Inventor before: Wang Juncha Inventor before: Wang Gang Inventor before: Hu Chunyi |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |